{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1581.6","upperLimit":"3494.2","value":"2350.9"},{"groupId":"OG001","lowerLimit":"3991.6","upperLimit":"9037.0","value":"6006.0"},{"groupId":"OG002","lowerLimit":"2791.7","upperLimit":"7204.7","value":"4484.8"}]}],"title":"Anti-HPV Type 6 (N=10, N=19, N=23)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2422.0","upperLimit":"5844.1","value":"3762.2"},{"groupId":"OG001","lowerLimit":"4520.8","upperLimit":"9386.8","value":"6514.2"},{"groupId":"OG002","lowerLimit":"5028.2","upperLimit":"8687.5","value":"6609.3"}]}],"title":"Anti-HPV Type 11 (N=10, N=19, N=23)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"973.2","upperLimit":"7961.8","value":"2783.6"},{"groupId":"OG001","lowerLimit":"8856.5","upperLimit":"18928.3","value":"12947.5"},{"groupId":"OG002","lowerLimit":"6570.9","upperLimit":"15542.6","value":"10105.9"}]}],"title":"Anti-HPV Type 16 (N=7, N=19, N=20)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"403.7","upperLimit":"2227.1","value":"948.2"},{"groupId":"OG001","lowerLimit":"3467.5","upperLimit":"7471.7","value":"5090.0"},{"groupId":"OG002","lowerLimit":"3135.2","upperLimit":"5285.9","value":"4070.9"}]}],"title":"Anti-HPV Type 18 (N=10, N=19, N=25)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.5","upperLimit":"88.2","value":"36.9"},{"groupId":"OG001","lowerLimit":"4876.7","upperLimit":"12408.5","value":"7779.0"},{"groupId":"OG002","lowerLimit":"3683.0","upperLimit":"8175.6","value":"5487.3"}]}],"title":"Anti-HPV Type 31 (N=11, N=22, N=24)"},{"categories":[{"measurements":[{"comment":"The lower bound of the 95% confidence interval is below the level of detectability (\\<4).","groupId":"OG000","lowerLimit":"NA","upperLimit":"10.9","value":"4.7"},{"groupId":"OG001","lowerLimit":"2680.5","upperLimit":"5894.0","value":"3974.8"},{"groupId":"OG002","lowerLimit":"3499.6","upperLimit":"6302.5","value":"4696.4"}]}],"title":"Anti-HPV Type 45 (N=11, N=20, N=24)"},{"categories":[{"measurements":[{"comment":"The GMT is \\<16, and the lower and upper bounds of the 95% confidence interval are below the level of detectability (\\<16 to \\<16).","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"3962.4","upperLimit":"8242.6","value":"5714.9"},{"groupId":"OG002","lowerLimit":"4919.9","upperLimit":"8919.9","value":"6624.6"}]}],"title":"Anti-HPV Type 52 (N=10, N=20, N=23)"},{"categories":[{"measurements":[{"comment":"The lower bound of the 95% confidence interval is below the level of detectability (\\<6).","groupId":"OG000","lowerLimit":"NA","upperLimit":"28.1","value":"9.6"},{"groupId":"OG001","lowerLimit":"3170.1","upperLimit":"7766.1","value":"4961.8"},{"groupId":"OG002","lowerLimit":"4036.3","upperLimit":"6676.5","value":"5191.2"}]}],"title":"Anti-HPV Type 58 (N=9, N=21, N=24)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"30"}],"units":"Participants"}],"description":"The quadrivalent HPV (GARDASIL™) vaccine has types 6, 11, 16, 18, and the octavalent HPV has types 6, 11, 16, 18, 31, 45, 52, and 58. Serum antibody titres to the HPV type were obtained using cLIA after vaccination with GARDASIL™ or the octavalent HPV vaccine. GMTs were calculated and are reported as the antibody concentration in milli-Merck Units per milliliter (mMU/mL) of neutralizing monoclonal antibody equivalent.","dispersionType":"95% Confidence Interval","groups":[{"description":"Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) for Phase B","id":"OG000","title":"qHPV (GARDASIL™) - Phase B Control"},{"description":"Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With 281 mcg Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and 60 mcg ISCOMATRIX™(IMX)","id":"OG001","title":"Octavalent HPV With 60 mcg IMX / AAHS"},{"description":"Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With 281 mcg Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and 120 mcg ISCOMATRIX™ (IMX)","id":"OG002","title":"Octavalent HPV With 120 mcg IMX / AAHS"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PPI population: All participants who were not protocol violators, received all 3 vaccinations within acceptable day ranges, were seronegative at Day 1 and PCR-negative Day 1 through Month 7\n\nfor the relevant HPV type(s), and had a valid Month 7 serology result collected in the appropriate day range.","reportingStatus":"POSTED","timeFrame":"4 weeks postdose 3 (Phase B)","title":"Geometric Mean Titers (GMTs) to Each of the HPV Types Contained in the Vaccine for Phase B","type":"PRIMARY","unitOfMeasure":"mMU/mL"}